found that TIGIT was overexpressed in CD4+ T cells, CD8 + T cells, and Tregs in patients with HNSCC, which is expected to be a new effective immune checkpoint besides PD-1/PD-L1 and CTLA-4. This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.